Lexicon Q3 net loss $50.5M ($0.21/sh); INPEFA revenue $0.4M since launch

LEXICON PHARMACEUTICALS, INC.

2023-Q3 EPS reported -$0.60 revenue$502,000

Net loss of $50.5M vs $23.4M a year ago; loss per share $0.21 vs $0.13.
Total Q3 revenue $0.2M; INPEFA net product revenues since June launch total $0.4M.
Express Scripts placed INPEFA on Premier Access, Premier Performance (Medicare) and Basic/High Performance (commercial) formularies effective Nov 1.
LX9211 Phase 2b enrollment expected to begin in December 2023 for diabetic peripheral neuropathic pain.
Cash and investments $218.4M as of Sept 30, 2023, up from $138.4M at Dec 31, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.